EMA Releases Report on Big Data

News
Article

A taskforce evaluated the advantage of using Big Data in the evaluation of the benefits versus risks of medications.

On Feb. 15, 2019, the European Medicines Agency (EMA) announced the publication of a summary report prepared by the Heads of Medicines Agencies (HMA)–EMA Joint Big Data taskforce.

The taskforce considered six subgroups of data sources (genomics, bioanalytical ‘omics, clinical trials, observational data, spontaneous adverse drug reactions data, and social media) to determine the use and benefit of these data to assess the benefits and risks of medications. Each subgroup provided recommendations on priorities and future actions for evaluation and use of data.

“The overarching conclusion is clear: much may be gained from the rational use of Big Data in a regulatory context for approval and monitoring of efficacy/effectiveness and safety of medicines, medical devices, and combinations thereof. Indeed, many future activities necessary for regulatory progress will not be possible without the use of Big Data technologies. AI [artificial intelligence] technologies offer particularly promising advances in these fields. It is however clear that without a systematic, coordinated and integrated European approach many of these advantages may not be gained,” the report states.

The taskforce includes drug regulators from 14 national competent authorities and EMA. Comments on the report by stakeholders and the public are being accepted until April 15, 2019.

Source: EMA

 

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes